Clinical Trials Directory

Trials / Completed

CompletedNCT00347269

Primary Care Intervention Strategy for Anxiety Disorders

Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
1,004 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study will compare the effectiveness of an intervention strategy for the treatment of people with post traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder in the primary care setting.

Detailed description

Anxiety disorders are highly prevalent, distressing, and disabling. Most patients with anxiety disorders who do receive mental health treatment receive it in primary care settings, where the quality of care is generally insufficient. This intervention is geared towards testing the clinical effectiveness of a care-manager assisted chronic disease management program for four common anxiety disorders (post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder) in the primary care setting. This approach has been shown to be effective for the treatment of depression. Participants in this randomized, controlled trial will either be assigned to the control group: treatment-as-usual (TAU) from their primary care provider (PCP); or to the intervention group: CALM (Coordinated Anxiety Learning and Management). Intervention subjects will choose to receive CBT, medication, or both for the treatment of their anxiety. Those who choose CBT will receive it from a study-trained Anxiety Clinical Specialist (ACS) in their respective clinic. For those who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participant's PCP. In this stepped-care design, subject progress will be formally re-evaluated at 8-12 week intervals. If treatment progress is not satisfactory, options include: additional or modified treatment with current modality, switching to the other treatment modality, or adding the other modality. When remission is attained, the ACS will follow-up with participants on a monthly basis to review progress and practice anxiety-reduction strategies. Treatment will continue for up to 12 months. Participants in both study arms will undergo formal baseline and outcome assessment interviews conducted at the 6, 12, and 18 month follow-up time-points.

Conditions

Interventions

TypeNameDescription
BEHAVIORALCognitive-behavioral therapyParticipants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
DRUGPsychotropic medication optimizationFor those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
BEHAVIORALTreatment as UsualParticipants in the control group will receive standard treatment from their PCP.

Timeline

Start date
2006-06-01
Primary completion
2009-10-01
Completion
2009-10-01
First posted
2006-07-04
Last updated
2017-05-19
Results posted
2017-05-19

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00347269. Inclusion in this directory is not an endorsement.